Spätfolgen in der Nachsorge von krebskranken Kindern und Jugendlichen

[1]  M. Blettner,et al.  [Follow up of long-term survivors after childhood cancer in Germany]. , 2005, Klinische Padiatrie.

[2]  H. Dörr,et al.  Prospective Multicenter Registration of Major Late Sequelae in Sarcoma Patients Using the Late Effects Surveillance System (LESS) , 2005, Klinische Padiatrie.

[3]  S. Lipsitz,et al.  Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Schrappe,et al.  Osteonecrosis: A treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)—experiences from trial ALL‐BFM 95 , 2005, Pediatric blood & cancer.

[5]  S. Bielack,et al.  Cisplatin-Induced Ototoxicity in Osteosarcoma Patients: A Report from the Late Effects Surveillance System , 2005, Cancer investigation.

[6]  Ralf Herold,et al.  Konzepte der GPOH und des Kompetenznetzes zur Weiterentwicklung und Qualitätssicherung in der Pädiatrischen Onkologie , 2004 .

[7]  A. Kulozik,et al.  [Scientific results in paediatric oncology and haematology]. , 2004, Klinische Padiatrie.

[8]  G. Schellong,et al.  Late Effects after Therapy of Hodgkin's Disease: Update 2003/04 on Overwhelming Post-Splenectomy Infections and Secondary Malignancies , 2004, Klinische Padiatrie.

[9]  W. Stöhr,et al.  Hearing function in soft tissue sarcoma patients after treatment with carboplatin: a report from the Late Effects Surveillance System. , 2004, Oncology reports.

[10]  S. Bielack,et al.  Late effects surveillance system for sarcoma patients , 2004, Pediatric blood & cancer.

[11]  H. Jürgens,et al.  [Transferring disease-oriented basic research into pediatric oncology]. , 2003, Klinische Padiatrie.

[12]  G. Henze,et al.  [Quality management within the competence network of paediatric oncology and haematology]. , 2003, Klinische Padiatrie.

[13]  J. Michaelis,et al.  Second malignant neoplasms after treatment of childhood cancer. , 2003, European journal of cancer.

[14]  S. Bielack,et al.  Die Überlebenden einer Krebserkrankung im Kindesalter Nachsorge und Spätfolgen nach erfolgreicher Therapie , 2002, Monatsschrift Kinderheilkunde.

[15]  G. Hausdorf,et al.  Multicentre analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No.9/GPOH and SIOP 93-01/GPOH. , 2002, Medical and pediatric oncology.

[16]  P. Martus,et al.  CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory. , 2002, Medical and pediatric oncology.

[17]  N. Graf,et al.  Augenbefunde bei Kindern mit Hirntumor - Datenbasis für einen Nachsorgeplan , 2002 .

[18]  E Glattre,et al.  Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Simone.  Late mortality in childhood cancer: two excellent studies bring good news tempered by room for improvement. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Dörr,et al.  Endokrine Spätfolgen nach Hirntumortherapie im Kindes- und Jugendalter: Literaturübersicht und Konzept einer prospektiven endokrinologischen Nachsorge , 2000 .

[21]  T. Langer,et al.  Basic methods and the developing structure of a late effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. For the German Late Effects Study Group in the German Society Pediatric Oncology and Hematology (GPOH). , 2000, Medical and pediatric oncology.

[22]  S. Kvaløy,et al.  Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease. , 1999, Acta oncologica.

[23]  M. Coulthard,et al.  Cisplatin dose rate as a risk factor for nephrotoxicity in children. , 1998, British Journal of Cancer.

[24]  W. Huk,et al.  CNS late effects after ALL therapy in childhood. Part II: Conventional EEG recordings in asymptomatic long-term survivors of childhood ALL--an evaluation of the interferences between neurophysiology, neurology, psychology, and CNS morphology. German Late Effects Working Group. , 1997, Medical and pediatric oncology.

[25]  M. Skalej,et al.  CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings in long-term survivors of childhood ALL--an evaluation of the interferences between morphology and neuropsychological performance. The German Late Effects Working Group. , 1997, Medical and pediatric oncology.

[26]  M. Hudson,et al.  Ultrasonography for thyroid screening after head and neck irradiation in childhood cancer survivors. , 1997, Medical and pediatric oncology.

[27]  S. Bielack,et al.  Die Nachsorge der von einer Krebserkrankung geheilten Kinder und jungen Erwachsenen. Erste Empfehlungen der Arbeitsgemeinschaft Spätfolgen , 1995 .

[28]  R. Jakacki,et al.  Restrictive lung disease following treatment for malignant brain tumors: a potential late effect of craniospinal irradiation. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Jürgens,et al.  Increased risk of ifosfamide-induced renal Fanconi's syndrome after unilateral nephrectomy , 1993, The Lancet.

[30]  D. Green,et al.  Late effects of treatment for childhood cancer , 1992 .

[31]  L. Robison,et al.  Second neoplasms after acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.

[32]  P. Clayton,et al.  Dose dependency of time of onset of radiation-induced growth hormone deficiency. , 1991, The Journal of pediatrics.

[33]  R. Mulhern,et al.  Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  A. Woodcock,et al.  Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. , 1990, The New England journal of medicine.